Submissions

CHPA wishes to draw attention to varying restrictions on how nonprescription medicines can be displayed or accessed among European Union Member States as a barrier to market entry for such products.

CHPA charged IOM to develop a proposed framework for categorizing and prioritizing DS ingredients based on safety issues, describe a process for developing a system of scientific reviews for evaluating the safety of DS ingredients, and develop at least six scientific reviews as prototypes for the system.

Comments before the White House Commission on Complementary and Alternative Medicine Policy on information development and dissemination.

Oral testimony of the Consumer Healthcare Products Association to the White House Commission on Complementary and Alternative Medicine Policy.

Letter to Charles Ganley, M.D. regarding the agency's determination and comments pertaining to psyllium.

This submission represents CHPA's detailed written comments as follow-up to the June meeting and is intended to complement the Association's oral presentation.

Comments on the safety evaluation of ephedra at the public meeting on the safety of dietary supplements containing ephedrine alkaloids.

CHPA presentations at Food and Drug Administration OTC Part 15 hearing - Over-the-Counter Medications: A Success Story.

CHPA submits these comments on the proposal published by the Food and Drug Administration in 64 Fed. Reg. 66822 (November 30, 1999) to revise its citizen petition regulations, 21 C.F.R. § 10.25 and 21 C.F.R. § 10.30.

CHPA submits these written comments in response to FDA’s notice in the Federal Register concerning “Guidance for Industry: Significant Scientific Agreement in the Review of Health Claims for Conventional Foods and Dietary Supplements.”